Merck Withdraws from COVID-19 Vaccine Race Due to Sub-par Response
January 25th, 2021 – Biopharma giant Merck who joined late in the COVID-19 vaccine race, has decided to pull the plug on two of its candidates, V590 and V591. The …
Read MoreThe Next Generation Biotech Media
January 25th, 2021 – Biopharma giant Merck who joined late in the COVID-19 vaccine race, has decided to pull the plug on two of its candidates, V590 and V591. The …
Read MoreJust a month after approving GSK’s Benlysta (belimumab), the FDA has now approved a second drug for treating lupus nephritis. On January 22nd, Candian biotech Aurinia Pharmaceuticals Inc. bagged the …
Read MoreThe paramount achievement in cancer treatment in the last decade has undoubtedly been the arrival of checkpoint inhibitors that relieve T cells from tumor-mediated suppression. It started with the approval …
Read MoreEli Lilly’s COVID-19 neutralizing antibody LY-CoV555 (Bamlanivimab), which previously failed in ACTIV-3 sub-study to add any clinical value to hospitalized patients, has been now shown to drastically reduce the risk …
Read MoreENHERTU (fam-trastuzumab deruxtecan-nxki), a product of a joint endeavor between AstraZeneca and Daiichi Sankyo, has bagged FDA approval for treating adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction …
Read MoreThe chances of getting a cure for Alzheimer’s disease took one more hit as another Alzheimer’s trial bit the dust. On January 18th, Biohaven Pharmaceuticals announced that its drug troriluzole, …
Read MoreJanuary 20th, 2021 – It has been a year since Merck announced a surprise Phase 3 success for Verquvo, a heart drug that it bought from Bayer for $1 billion. …
Read MoreOn January 15th, Pfizer announced FDA approval for its tyrosine kinase inhibitor, Xalkori, which can be used in pediatric patients one year of age and older and young adults with …
Read MoreAs SARS-CoV-2, the causative agent for COVID-19, continues to cause rampant destruction on human lives globally, biopharma companies are stepping up their game to provide some relief. The latest one …
Read MoreAfter delivering a stellar performance last year, Alnylam, a leading RNAi therapeutics company, is now eyeing a position in the top 5 biotech companies in market cap by 2025. At …
Read More